WAVE Life Sciences Garners $66,000,000 Series B Funding
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=b9fa2e2b-b4a1-4d26-9185-2b7a3a2b8e02
Date 8/18/2015
Company Name WAVE Life Sciences
Mailing Address 419 Western Avenue Boston, MA 02135 USA
Company Description WaVe Life Sciences is leading a revolution in nucleic acid therapeutics and was founded on the core principle that medicines should possess precisely controlled molecular structures. We and our strategic partners are advancing a portfolio of stereopure drug candidates that target underlying biology across a wide range of human diseases.
Proceeds Purposes WAVE expects to use the proceeds from the Series B financing to continue to evolve its chemistry platform and advance a broad pipeline of stereopure nucleic acid therapeutics, including candidates for Huntington’s disease and Duchenne muscular dystrophy, across a breadth of oligonucleotide modalities, including RNAi, antisense and exon-skipping, among others. The company plans to file its first INDs by the end of 2016.
M&A Terms
Venture Investor Foresite Capital
Venture Investor Fidelity Management & Research Company